Similarly, methenyltetrahydrofolate cyclohydrolase (MTHFD2) has recently been identified as a novel modulator of the EMT marker vimentin [60] and reported to be a potential pharmaceutical target in advanced cancers [61]. This evidence concerns the gene VIM and cancer.